FMP
CinCor Pharma, Inc.
CINC
NASDAQ
Inactive Equity
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
29.06 USD
0 (0%)
About
ceo
Mr. Marc M. P. de Garidel
sector
Healthcare
industry
Biotechnology
website
https://www.cincor.com
exchange
NASDAQ
Description
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
CIK
0001868734
ISIN
US17240Y1091
CUSIP
17240Y109
Address
200 Clarendon Street
Phone
844 531 1834
Country
US
Employee
19
IPO Date
Jan 7, 2022
Summary
CIK
0001868734
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
17240Y109
ISIN
US17240Y1091
Country
US
Price
29.06
Beta
0
Volume Avg.
625.75k
Market Cap
1.27B
Shares
-
52-Week
10.53-43.15
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-14.46
P/B
-
Website
https://www.cincor.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CINC News
It looks like there's no news available.
